BIORESTORATIVE THERAPIES REPORTS POSITIVE PHASE 2 BLINDED DATA FOR BRTX-100 DEMONSTRATING MEANINGFUL IMPROVEMENTS IN PAIN AND FUNCTION IN CHRONIC LUMBAR DISC DISEASE
BIORESTORATIVE THERAPIES INC - REPORTS PHASE 2 DATA FOR BRTX-100 WITH 50%+ PATIENTS SHOWING >50% IMPROVEMENT
BIORESTORATIVE THERAPIES INC - NO ADVERSE EVENTS RELATED TO DOSE-LIMITING TOXICITIES ASSOCIATED WITH HYPOXIC-CULTURED MESENCHYMAL STEM CELLS
Source text: ID:nGNX3K33mT
Further company coverage: BRTX.O
((Reuters.Briefs@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments